**Supplementary Table 2 Subgroup analysis for the main potential confounding factors with fixed effects model**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Subgroup | Number of study | OR | lower | upper | I2 | P-value |
| Overall | 15 | 6.74 | 4.46 | 10.2 | 35.50% | 0.0847 |
| Age<65 | 6 | 8.91 | 5.59 | 14.2 | 39.00% |  |
| Age>=65 | 5 | 4.88 | 2.76 | 8.63 | 33.20% | 0.0801 |
| Stage I<50.45% | 4 | 16.15 | 8.04 | 31.05 | 47.00% |  |
| Stage I>=50.45% | 3 | 10.85 | 6.68 | 17.62 | 0.00% | 0.05 |
| Stage I+II<65% | 6 | 10.4 | 6.58 | 16.43 | 42.00% |  |
| Stage I+II>=65% | 5 | 5.83 | 3.37 | 10.11 | 37.00% | 0.11 |
| M2F<69% | 6 | 10.17 | 5.63 | 18.36 | 19.00% |  |
| M2F>=69% | 5 | 7.89 | 4.55 | 13.67 | 10.60% | 0.62 |
| MSP | 10 | 5.98 | 4.2 | 8.51 | 12.30% |  |
| qMSP | 5 | 6.34 | 3.31 | 12.13 | 65.00% | 0.44 |
| Diagnose | 6 | 3.48 | 2.18 | 5.58 | 0.00% |  |
| Non-diagnose | 9 | 9.26 | 6.13 | 13.97 | 9.00% | 0.002 |
| Multiple targets | 14 | 5.98 | 4.36 | 8.2 | 39.60% |  |
| Single target | 1 | 8.62 | 1.8 | 41.41 | - | 0.83 |
| Heterogeneous | 4 | 5.6 | 2.58 | 12.16 | 59.70% |  |
| Autogenous | 11 | 6.15 | 4.39 | 8.63 | 29.60% | 0.72 |
| Plasma | 4 | 5.6 | 2.58 | 12.16 | 59.70% |  |
| Tissue | 11 | 6.15 | 4.39 | 8.63 | 29.60% | 0.72 |
| Ad%<65% | 4 | 7.8 | 4.68 | 12.99 | 0.00% |  |
| Ad%>=65% | 9 | 7.63 | 5.05 | 11.54 | 52.00% | 0.95 |
| Asian | 9 | 6.79 | 4.7 | 9.81 | 31.00% |  |
| Caucasian | 6 | 8.11 | 4.88 | 13.5 | 55.00% | 0.58 |
| Primerset I | 11 | 7.82 | 1.91 | 12.69 | 35.00% |  |
| Primerset II | 1 | 2.75 | 1.20 | 6.32 | - |  |
| Primerset III | 1 | 15.25 | 3.44 | 67.53 | - |  |
| Primerset IV | 1 | 29.75 | 1.70 | 521.15 | - | 0.06 |